DAYBUE net sales US$87.1 million in Q4 2023
Filed with ASX · · 2 pages · English
Neuren Pharmaceuticals Limited on 6ix
In the deck
Earlier from Neuren Pharmaceuticals
- Comment on research report
- Q4 2023 Appendix 4C Cash Flow Report
- Q4 2023 quarterly activity report
- Completion of enrolment in Neuren's Angelman P2 trial
- Investor presentation, 18 December 2023
Later from Neuren Pharmaceuticals
- Appendix 4E and 2023 full year accounts
- Neuren reports profit of $157 million for 2023
- Trofinetide accepted for Priority Review by Health Canada
- Q1 2024 quarterly activity and cash flow report
- DAYBUE Q1 net sales US$75.9m, full-year guidance US$370-420m
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals